Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency

Molecular Genetics and Metabolism

Volumn 105, Issue 2, 2012, Pages 263-265

  Wilson, James M ^a   Shchelochkov, Oleg A ^b   Gallagher, Renata C ^c   Batshaw, Mark L ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF IOWA CHILDREN S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

^d CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Adenovirus; Gene therapy; Hepatocellular carcinoma (HCC); Ornithine transcarbamylase deficiency (OTCD); Urea cycle disorders (UCDs)

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; AMMONIA; CREATININE; ORNITHINE CARBAMOYLTRANSFERASE; OROTIC ACID;

ADENOVIRUS 5; ADULT; AGED; ARGININOSUCCINIC ACIDURIA; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEMALE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; HYPERAMMONEMIA; LETHARGY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER METASTASIS; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PRESCHOOL CHILD; PRIORITY JOURNAL; VIRAL GENE THERAPY; VIRUS CARCINOGENESIS;

ADENOVIRIDAE; AGED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; GENE THERAPY; HETEROZYGOTE; HUMANS; LIVER NEOPLASMS; ORNITHINE CARBAMOYLTRANSFERASE; ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY DISEASE; UREA CYCLE DISORDERS, INBORN;

ADENOVIRIDAE;

EID: 84856089300     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.10.016     Document Type: Article

References (27)

1. Raper S.E., Yudkoff M., Chirmule N., Gao G.P., Nunes F., Haskal Z.J., Furth E.E., Propert K.J., Robinson M.B., Magosin S., Simoes H., Speicher L., Hughes J., Tazelaar J., Wivel N.A., Wilson J.M., Batshaw M.L. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 2002, 13:163-175.
2. Seminara J., Tuchman M., Krivitzky L., Krischer J., Lee H.S., Lemons C., Baumgartner M., Cederbaum S., Diaz G.A., Feigenbaum A., Gallagher R.C., Harding C.O., Kerr D.S., Lanpher B., Lee B., Lichter-Konecki U., McCandless S.E., Merritt J.L., Oster-Granite M.L., Seashore M.R., Stricker T., Summar M., Waisbren S., Yudkoff M., Batshaw M.L. Establishing a consortium for the study of rare diseases: the Urea Cycle Disorders Consortium. Mol. Genet. Metab. 2010, 100(Suppl. 1):S97-S105.
3. Tuchman M., Lee B., Lichter-Konecki U., Summar M.L., Yudkoff M., Cederbaum S.D., Kerr D.S., Diaz G.A., Seashore M.R., Lee H.S., McCarter R.J., Krischer J.P., Batshaw M.L. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol. Genet. Metab. 2008, 94:397-402.
4. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., Asnafi V., MacIntyre E., Dal Cortivo L., Radford I., Brousse N., Sigaux F., Moshous D., Hauer J., Borkhardt A., Belohradsky B.H., Wintergerst U., Velez M.C., Leiva L., Sorensen R., Wulffraat N., Blanche S., Bushman F.D., Fischer A., Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118:3132-3142.
5. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., Gilmour K.C., Adams S., Thornhill S.I., Parsley K.L., Staal F.J., Gale R.E., Linch D.C., Bayford J., Brown L., Quaye M., Kinnon C., Ancliff P., Webb D.K., Schmidt M., von Kalle C., Gaspar H.B., Thrasher A.J. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 2008, 118:3143-3150.
6. Van der Eb A.J., Mulder C., Graham F.L., Houweling A. Transformation with specific fragments of adenovirus DNAs. I. Isolation of specific fragments with transforming activity of adenovirus 2 and 5 DNA. Gene 1977, 2:115-132.
7. F.D.A.U.S. Department of Health and Human Services Center for biologics evaluation and research. Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events 2006, 6/18/2009 [cited 2011 September 22]; Available from. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072957.htm.
8. Roy S., Vandenberghe L.H., Kryazhimskiy S., Grant R., Calcedo R., Yuan X., Keough M., Sandhu A., Wang Q., Medina-Jaszek C.A., Plotkin J.B., Wilson J.M. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog. 2009, 5:e1000503.
9. Aida S., Ogata T., Kamota T., Nakamura N. Primary ornithine transcarbamylase deficiency. A case report and electron microscopic study. Acta Pathol. Jpn. 1989, 39:451-456.
10. Capistrano-Estrada S., Marsden D.L., Nyhan W.L., Newbury R.O., Krous H.F., Tuchman M. Histopathological findings in a male with late-onset ornithine transcarbamylase deficiency. Pediatr. Pathol. 1994, 14:235-243.
11. Landrieu P., Francois B., Lyon G., Van Hoof F. Liver peroxisome damage during acute hepatic failure in partial ornithine transcarbamylase deficiency. Pediatr. Res. 1982, 16:977-981.
12. Mustafa A., Clarke J.T. Ornithine transcarbamoylase deficiency presenting with acute liver failure. J. Inherit. Metab. Dis. 2006, 29:586.
13. Shapiro J.M., Schaffner F., Tallan H.H., Gaull G.E. Mitochondrial abnormalities of liver in primary ornithine transcarbamylase deficiency. Pediatr. Res. 1980, 14:735-739.
14. Tallan H.H., Schaffner F., Taffet S.L., Schneidman K., Gaull G.E. Ornithine carbamoyltransferase deficiency in an adult male patient: significance of hepatic ultrastructure in clinical diagnosis. Pediatrics 1983, 71:224-232.
15. Teufel U., Weitz J., Flechtenmacher C., Prietsch V., Schmidt J., Hoffmann G.F., Kolker S., Engelmann G. High urgency liver transplantation in ornithine transcarbamylase deficiency presenting with acute liver failure. Pediatr. Transplant. 2011, 15:E110-E115.
16. Zammarchi E., Donati M.A., Filippi L., Resti M. Cryptogenic hepatitis masking the diagnosis of ornithine transcarbamylase deficiency. J. Pediatr. Gastroenterol. Nutr. 1996, 22:380-383.
17. Hagiwara N., Sekijima Y., Takei Y., Ikeda S., Kawasaki S., Kobayashi K., Saheki T. Hepatocellular carcinoma in a case of adult-onset type II citrullinemia. Intern. Med. 2003, 42:978-982.
18. Soeda J., Yazaki M., Nakata T., Miwa S., Ikeda S., Hosoda W., Iijima M., Kobayashi K., Saheki T., Kojiro M., Miyagawa S. Primary liver carcinoma exhibiting dual hepatocellular-biliary epithelial differentiations associated with citrin deficiency: a case report. J. Clin. Gastroenterol. 2008, 42:855-860.
19. Tsai C.W., Yang C.C., Chen H.L., Hwu W.L., Wu M.Z., Liu K.L., Wu M.S. Homozygous SLC25A13 mutation in a Taiwanese patient with adult-onset citrullinemia complicated with steatosis and hepatocellular carcinoma. J. Formos. Med. Assoc. 2006, 105:852-856.
20. Chang K.W., Chen H.L., Chien Y.H., Chen T.C., Yeh C.T. SLC25A13 gene mutations in Taiwanese patients with non-viral hepatocellular carcinoma. Mol. Genet. Metab. 2011, 103:293-296.
21. Cheng P.N., Lam T.L., Lam W.M., Tsui S.M., Cheng A.W., Lo W.H., Leung Y.C. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007, 67:309-317.
22. Dillon B.J., Prieto V.G., Curley S.A., Ensor C.M., Holtsberg F.W., Bomalaski J.S., Clark M.A. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004, 100:826-833.
23. Lam T.L., Wong G.K., Chong H.C., Cheng P.N., Choi S.C., Chow T.L., Kwok S.Y., Poon R.T., Wheatley D.N., Lo W.H., Leung Y.C. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett. 2009, 277:91-100.
24. Erez A., Shchelochkov O.A., Plon S.E., Scaglia F., Lee B. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am. J. Hum. Genet. 2011, 88:402-421.
25. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999, 340:745-750.
26. Nunes F.A., Furth E.E., Wilson J.M., Raper S.E. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum. Gene Ther. 1999, 10:2515-2526.
27. Bell P., Moscioni A.D., McCarter R.J., Wu D., Gao G., Hoang A., Sanmiguel J.C., Sun X., Wivel N.A., Raper S.E., Furth E.E., Batshaw M.L., Wilson J.M. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol. Ther. 2006, 14:34-44.